Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Clinical trials for negative symptoms--emerging directions and unresolved issues.

Marder SR, Rabinowitz J, Kapur S.

Schizophr Res. 2013 Nov;150(2-3):327. doi: 10.1016/j.schres.2013.10.005. No abstract available.

PMID:
24209763
[PubMed - indexed for MEDLINE]
2.

Pharmacological approaches to treating negative symptoms: a review of clinical trials.

Arango C, Garibaldi G, Marder SR.

Schizophr Res. 2013 Nov;150(2-3):346-52. doi: 10.1016/j.schres.2013.07.026. Epub 2013 Aug 9. Review.

PMID:
23938176
[PubMed - indexed for MEDLINE]
3.

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.

Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J.

Schizophr Res. 2013 Nov;150(2-3):328-33. doi: 10.1016/j.schres.2013.07.058. Epub 2013 Sep 9. Review.

PMID:
24028744
[PubMed - indexed for MEDLINE]
4.

Schizophrenia drug gets negative results for negative symptoms.

Kingwell K.

Nat Rev Drug Discov. 2014 Apr;13(4):244-5. doi: 10.1038/nrd4294. No abstract available.

PMID:
24687052
[PubMed - indexed for MEDLINE]
5.

Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Honer WG, Thornton AE, Sherwood M, MacEwan GW, Ehmann TS, Williams R, Kopala LC, Procyshyn R, Barr AM.

CNS Drugs. 2007;21(9):699-714. Review.

PMID:
17696571
[PubMed - indexed for MEDLINE]
6.

Concordance between measures of functioning, symptoms, and change: examining the GAF, CGI-S, CGI-C, and PANSS.

Rabinowitz J, Levine S, Martinez G.

J Clin Psychopharmacol. 2010 Aug;30(4):478-80. doi: 10.1097/JCP.0b013e3181e7145f. No abstract available.

PMID:
20631575
[PubMed - indexed for MEDLINE]
7.

[The antipsychotic drug aripiprazole (ABILIFY)].

Hirose T, Mamiya N, Yamada S, Taguchi M, Kameya T, Kikuchi T.

Nihon Yakurigaku Zasshi. 2006 Nov;128(5):331-45. Review. Japanese. No abstract available.

PMID:
17102579
[PubMed - indexed for MEDLINE]
8.

Drugs for psychotic disorders.

[No authors listed]

Treat Guidel Med Lett. 2010 Aug;8(96):61-4; quiz two pages following last numbered page.. No abstract available.

PMID:
20651640
[PubMed - indexed for MEDLINE]
9.

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

Silver H.

Int Clin Psychopharmacol. 2003 Nov;18(6):305-13. Review.

PMID:
14571150
[PubMed - indexed for MEDLINE]
10.

Clinical use of the newer antipsychotic drugs.

Perry PJ.

Am J Health Syst Pharm. 1995 Feb 1;52(3 Suppl 1):S9-14. Review.

PMID:
7538437
[PubMed - indexed for MEDLINE]
11.

Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series.

Gama CS, Lucena DD, Cruz C, Lobato MI, Belmonte-de-Abreu PS.

Rev Bras Psiquiatr. 2010 Jun;32(2):193-4. No abstract available.

PMID:
20658059
[PubMed - indexed for MEDLINE]
Free Article
12.

Cognition in schizophrenia: summary Nice Consultation Meeting 2012.

Nutt D, Gispen-de Wied CC, Arango C, Keefe RS, Penad├ęs R, Murphy DG, Robbins TW, Sahakian BJ.

Eur Neuropsychopharmacol. 2013 Aug;23(8):769-78. doi: 10.1016/j.euroneuro.2013.03.005. Epub 2013 May 15. No abstract available.

PMID:
23684476
[PubMed - indexed for MEDLINE]
13.

Do negative symptoms respond to pharmacological treatment?

Kane JM, Mayerhoff D.

Br J Psychiatry Suppl. 1989 Nov;(7):115-8. Review. No abstract available.

PMID:
2575914
[PubMed - indexed for MEDLINE]
14.

Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.

Brown LA, Levin GM.

Pharmacotherapy. 1998 Jan-Feb;18(1):69-83. Review.

PMID:
9469684
[PubMed - indexed for MEDLINE]
15.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Coyle JT, Tsai G, Goff D.

Ann N Y Acad Sci. 2003 Nov;1003:318-27. Review.

PMID:
14684455
[PubMed - indexed for MEDLINE]
16.

Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences.

Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Stauffer V, Menard F, Kinon BJ, Kapur S.

Schizophr Res. 2013 Nov;150(2-3):334-8. doi: 10.1016/j.schres.2013.06.023. Epub 2013 Jun 29.

PMID:
23815975
[PubMed - indexed for MEDLINE]
17.

Blonanserin: a review of its use in the management of schizophrenia.

Deeks ED, Keating GM.

CNS Drugs. 2010 Jan;24(1):65-84. doi: 10.2165/11202620-000000000-00000. Review.

PMID:
20030420
[PubMed - indexed for MEDLINE]
18.

Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.

Kasper S.

Int Clin Psychopharmacol. 2002 Dec;17 Suppl 4:S19-26. Review.

PMID:
12685918
[PubMed - indexed for MEDLINE]
19.

Methodological issues in negative symptom trials.

Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS.

Schizophr Bull. 2011 Mar;37(2):250-4. doi: 10.1093/schbul/sbq161. Epub 2011 Jan 26.

PMID:
21270473
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Methodological and design issues in clinical trials of new neuroleptics: an overview.

Awad AG.

Br J Psychiatry Suppl. 1993 Dec;(22):51-7. Review.

PMID:
7906524
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk